Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE(Thomas Jefferson University)(Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE(Thomas Jefferson University))

概要

基本信息

药物类型

疫苗

别名-

靶点

GC-C

作用机制

GC-C拮抗剂(热稳定肠毒素受体拮抗剂)

治疗领域-

在研适应症-

非在研适应症-

原研机构

Thomas Jefferson University

在研机构

Thomas Jefferson University

非在研机构-

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

1

项与 Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE(Thomas Jefferson University) 相关的临床试验

NCT04111172

/ Active, not recruiting临床2期IIT

A Phase 2A, Dose-Finding Study of Ad5.F35-hGCC-PADRE Vaccine in Adults With Gastrointestinal Adenocarcinomas at Risk of Relapse Post Definitive Surgery and Standard Therapy

This phase IIA trial investigates the side effects of Ad5.F35-hGCC-PADRE vaccine and to see how well it works in treating patients with gastrointestinal adenocarcinoma. Ad5.F35-hGCC-PADRE vaccine may help to train the patient's own immune system to identify and kill tumor cells and prevent it from coming back.

开始日期2020-11-10

申办/合作机构

Thomas Jefferson University

100 项与 Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE(Thomas Jefferson University) 相关的临床结果

登录后查看更多信息

100 项与 Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE(Thomas Jefferson University) 相关的转化医学

登录后查看更多信息

100 项与 Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE(Thomas Jefferson University) 相关的专利（医药）

登录后查看更多信息

100 项与 Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE(Thomas Jefferson University) 相关的药物交易

登录后查看更多信息